-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cowen Boosts FibroGen (NASDAQ:FGEN) Price Target to $14.00
Cowen Boosts FibroGen (NASDAQ:FGEN) Price Target to $14.00
FibroGen (NASDAQ:FGEN – Get Rating) had its price objective boosted by stock analysts at Cowen to $14.00 in a research report issued on Monday, Stock Target Advisor reports. Cowen's price target suggests a potential downside of 4.04% from the stock's current price.
A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th.
Get FibroGen alerts:FibroGen Stock Up 0.7 %
FGEN traded up $0.10 on Monday, reaching $14.59. The company had a trading volume of 424,401 shares, compared to its average volume of 876,948. The stock has a 50-day moving average price of $11.91 and a 200-day moving average price of $11.98. FibroGen has a 1 year low of $7.81 and a 1 year high of $16.91. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.16 and a beta of 0.87.
FibroGen (NASDAQ:FGEN – Get Rating) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The business had revenue of $29.81 million during the quarter, compared to analysts' expectations of $36.15 million. During the same period in the prior year, the company earned ($1.45) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. As a group, analysts expect that FibroGen will post -3 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,200 shares during the period. Quantbot Technologies LP acquired a new position in shares of FibroGen during the second quarter worth about $39,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of FibroGen during the first quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in shares of FibroGen during the second quarter worth about $59,000. Finally, Advisor Group Holdings Inc. increased its stake in shares of FibroGen by 90.6% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after acquiring an additional 4,236 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
- Here's How the Inflation Reduction Act Energizes Power Stock
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
FibroGen (NASDAQ:FGEN – Get Rating) had its price objective boosted by stock analysts at Cowen to $14.00 in a research report issued on Monday, Stock Target Advisor reports. Cowen's price target suggests a potential downside of 4.04% from the stock's current price.
據Stock Target Advisor報道,考恩的股票分析師在週一發佈的一份研究報告中將FibroGen(納斯達克:FDEN-GET評級)的目標價上調至14.00美元。考恩的目標價表明,該股目前的價格可能下跌4.04%。
A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th.
其他一些股票研究分析師最近也對該股發表了評論。在8月10日星期三的一份報告中,StockNews.com將FibroGen的股票評級從“買入”下調至“持有”。高盛夫婦將FibroGen的股票目標價從9.00美元下調至8.00美元,並在5月24日(星期二)的一份報告中為該公司設定了“賣出”評級。
FibroGen Stock Up 0.7 %
FibroGen股價上漲0.7%
FGEN traded up $0.10 on Monday, reaching $14.59. The company had a trading volume of 424,401 shares, compared to its average volume of 876,948. The stock has a 50-day moving average price of $11.91 and a 200-day moving average price of $11.98. FibroGen has a 1 year low of $7.81 and a 1 year high of $16.91. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.16 and a beta of 0.87.
週一,fgen的交易價格上漲了0.1美元,達到14.59美元。該公司的成交量為424,401股,而其平均成交量為876,948股。該股的50日移動均線價格為11.91美元,200日移動均線價格為11.98美元。FibroGen的一年低點為7.81美元,一年高位為16.91美元。該股市值13.7億美元,市盈率為-6.16,貝塔係數為0.87。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,200 shares during the period. Quantbot Technologies LP acquired a new position in shares of FibroGen during the second quarter worth about $39,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of FibroGen during the first quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in shares of FibroGen during the second quarter worth about $59,000. Finally, Advisor Group Holdings Inc. increased its stake in shares of FibroGen by 90.6% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after acquiring an additional 4,236 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
機構投資者和對衝基金最近對他們在該公司的頭寸進行了調整。NISA Investment Advisors LLC在第二季度增持了369.7%的FibroGen股票。NISA Investment Advisors LLC現在持有這家生物製藥公司2,795股股票,價值30,000美元,在此期間又購買了2,200股。Quantbot Technologies LP在第二季度收購了FibroGen股票的新頭寸,價值約3.9萬美元。Dixon Hughes Goodman Wealth Advisors LLC在第一季度收購了FibroGen股票的新頭寸,價值約59,000美元。Lazard Asset Management LLC在第二季度收購了FibroGen股票的新頭寸,價值約5.9萬美元。最後,Advisor Group Holdings Inc.在第四季度增持了90.6%的FibroGen股票。Advisor Group Holdings Inc.在此期間增持了4,236股,目前持有這家生物製藥公司8,909股股票,價值130,000美元。77.35%的股票目前由機構投資者和對衝基金持有。
FibroGen Company Profile
FibroGen公司簡介
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物製藥公司,發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat,該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發,並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
- Here's How the Inflation Reduction Act Energizes Power Stock
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- 第二季度財報季最熱門的五個電話
- 以下是一個簡單的4只股票投資組合,它可以跑贏大盤
- AMC娛樂公司是在對猩猩採取快速行動嗎?
- 機構調整高收益Foot Locker,Inc.的控股
- 以下是《降低通脹法案》如何提振電力庫存
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧